MauiDerm NP+PA Fall 2019

Wednesday, October 2, 2019, 7:30 AM - Saturday, October 5, 2019, 5:00 PM, Omni Grove Park Inn

AMA PRA Category 1 Credits™ (29.25 hours), AMA PRA Category 1 Credits™ Designated (29.25 hours)

This 4-day, comprehensive, educational activity will begin with a pre-conference day. The pre-conference day is divided into multiple learning tracks based upon the learners’ identified needs/level(s) of expertise. The entire CE/CME program will utilize evidence-based data and best practices for the diagnosis and management of medical dermatologic conditions/diseases as well as surgical and aesthetic procedures in order to validate current practice patterns while updating skills in a variety of clinical areas. Case studies, panel discussions, didactic presentations, audience-response system, a meeting application that allows questions to be addressed to the podium moderator and hands-on workshops enhance the relevancy of the data presented and allow clinicians the ability apply this information into clinical practice.

To register, please go to: www.mauiderm.com

Registration Fees:

1. Review the pathogenesis of various dermatological conditions such as infectious diseases, psoriasis, psoriatic arthritis, acne vulgaris, rosacea, hidradenitis, contact dermatitis, atopic dermatitis, eczema, pruritus, actinic keratoses, melanoma and non-melanoma skin cancer, pediatric skin disorders, immunobullous diseases, granulomatous disorders of the skin, connective tissue diseases, hair and nail disorders, leg ulcers, oral lesions and life-threatening dermatoses such as TEN in order to accurately diagnose and improve upon the management of these conditions in patients
2. Cite the mechanisms of action of various drugs, including topical and systemic therapies, as well as immunomodulatory agents that are commonly prescribed by the nurse practitioner and physician assistant practicing in dermatology and identify patients in your practice for whom these therapies may be appropriate
3. Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving surgical and cosmetic procedures in order to set realistic expectations and maximize therapeutic outcomes
4. Describe potential adverse events, safety, tolerance and resistance issues that may be related to the use of various drugs and therapies prescribed by clinicians in dermatology as well as therapeutic modalities including: topical and systemic corticosteroids, newer biologic agents, including TNF antagonists, T-cell and B-cell targeted therapies, anti-IL-12/23 therapies, IL-23 & IL-17 antibodies, systemic and topical PDE4 inhibitors, JAK inhibitors, anti-IgE and anti-IL 4 receptor, systemic retinoids, methotrexate, cyclosporine, neurokinin-1 receptor antagonists, systemic and topical acne/rosacea therapies, oral and topical antibiotics, antifungals, anti-viral therapies, wound healing agents, antihistamines, calcineurin inhibitors, topical skin lightening agents, sunscreens, topical and systemic retinoids, 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, hedgehog pathway inhibitors, rituximab, BRAF/MEK inhibitors, CTLA-4 and PD-1/PDL-1 inhibitors, botulinum toxins, dermal filler agents including hyaluronic acid, collagen, polylactic acid, hydroxyappetite based fillers, and implement appropriate management strategies in order to reduce these adverse effects and optimize patient outcomes
5. Assess the data around emerging and novel therapeutics for a variety of dermatologic diseases and develop treatment algorithms and management strategies for the optimal use of these therapies
6. Discuss the importance of clinician/patient communication regarding benefit versus risk, patient satisfaction, and adherence when selecting therapies for patients

This Activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Advances in Cosmetic & Medical Dermatology.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 29.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Disclaimer Statement

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Omni Grove Park Inn

290 Macon Ave

Asheville, NC 28804

No faculty are available for this activity at this time.